TauRx is developing a potential treatment for Alzheimer’s disease by targeting the tau pathological process. Our experimental compound involved in clinical trials belongs to a class of drugs known as Tau Aggregation Inhibitors (TAIs). TAIs act by preventing the formation of and dissolving tau aggregates in the brain, thereby preserving normal tau function, which is essential for a healthy brain.
By undoing the tangles that cause dementia, we aim to slow and potentially stop memory loss.
TauRx has “composition of matter” patents and “use” patents covering the application of its TAIs for the treatment and prevention of Alzheimer’s and FTD. The company is also exploring the use of TAIs in several other neurodegenerative diseases associated with tau pathology, as well as other disorders deriving from the aggregation of other proteins in the brain, including Parkinson’s disease and Huntington’s disease.